Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Pelthos Therapeutics Inc.AMEX: PTHS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 24440.6% from a year ago
Cash & equivalents stood at $32.23M at the end of Q1 FY2026, up 24440.6% from a year earlier and up 78.8% from the prior quarter. Over 3 fiscal years it compounded at +589.1% a year.
Context
- Cash & equivalents amounted to 22.2% of total assets at the end of Q1 FY2026, up 7.8 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +24440.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 18.02M USD
- Year-over-year change
- +3410.2%
- 3-year CAGR
- +589.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.02M | +3410.2% |
| FY2024 | 2024-12-31 | 513.44K | +432.7% |
| FY2023 | 2023-12-31 | 96.39K | +75.0% |
| FY2022 | 2022-12-31 | 55.07K | — |
Cash & Equivalents vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 cash & equivalents of $32.23M is the highest of the 4 companies compared; the peer median is $3.25M.
- Its year-over-year change of +24440.6% is the highest of 4, against a peer median of +134.8%.
- Cash & equivalents amounts to 22.2% of total assets for PTHS, versus a peer median of 29.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.23M | +24440.6% | +589.1% | 22.2% | |
| Mar 2026 | $25.89M | +172.0% | +26.9% | 83.9% | |
| Mar 2026 | $3.25M | +134.8% | -1.6% | 29.9% | |
| Dec 2025 | $2.01M | -39.2% | -65.7% | 0.1% | |
| Peer median (excluding PTHS) | $3.25M | +134.8% | -1.6% | 29.9% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.